CR20180335A - CD40L INHIBITING POLYPEPTIDES - Google Patents
CD40L INHIBITING POLYPEPTIDESInfo
- Publication number
- CR20180335A CR20180335A CR20180335A CR20180335A CR20180335A CR 20180335 A CR20180335 A CR 20180335A CR 20180335 A CR20180335 A CR 20180335A CR 20180335 A CR20180335 A CR 20180335A CR 20180335 A CR20180335 A CR 20180335A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cd40l
- polypeptides
- inhibiting polypeptides
- immunoglobulins
- present
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 108010029697 CD40 Ligand Proteins 0.000 title abstract 3
- 102100032937 CD40 ligand Human genes 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 229940072221 immunoglobulins Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a inmunoglobulinas que se unen específicamente a CD40L y más en particular a polipéptidos, ácidos nucleicos que codifican dichos polipéptidos; a métodos para preparar tales polipéptidos; a composiciones y en particular a composiciones farmacéuticas que comprenden tales polipéptidos, con fines profilácticos, terapéuticos o de diagnóstico. En particular, las inmunoglobulinas de la presente invención inhiben la actividad de CD40L y son seguras.The present invention relates to immunoglobulins that specifically bind to CD40L and more particularly to polypeptides, nucleic acids encoding said polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions comprising such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260411P | 2015-11-27 | 2015-11-27 | |
| PCT/EP2016/079048 WO2017089618A1 (en) | 2015-11-27 | 2016-11-28 | Polypeptides inhibiting cd40l |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180335A true CR20180335A (en) | 2018-11-01 |
Family
ID=64565311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180335A CR20180335A (en) | 2015-11-27 | 2016-11-28 | CD40L INHIBITING POLYPEPTIDES |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20180335A (en) |
-
2016
- 2016-11-28 CR CR20180335A patent/CR20180335A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000128A (en) | CD40L INHIBITING POLYPEPTIDES | |
| MX2023000818A (en) | Anti-ctla-4 antibodies and methods of use thereof. | |
| AR112069A1 (en) | IMMUNOGLOBULINS THAT BIND AGGRECAN | |
| MX2025006169A (en) | Mmp13 binding immunoglobulins | |
| MX2023008693A (en) | Modulatory polynucleotides. | |
| EA201890630A1 (en) | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| BR112015031073A2 (en) | bicyclic bromodomain inhibitors | |
| BR112017023374A2 (en) | anti-cgrp antibody formulation | |
| EA201492221A1 (en) | POLYPEPTIDES THAT HAVE A TRANSGALACTOSIS ACTIVITY | |
| CL2014002077A1 (en) | Pharmaceutical composition comprising dimethyl fumarate; Preparation method; capsule comprising microtablets of dimethyl fumarate; method for the treatment, prophylaxis or improvement of multiple sclerosis. | |
| HK1258509A1 (en) | Gitr agonists | |
| BR112016017041A2 (en) | ISOLATED PROTEIN HAVING PHOSPHATASE ACTIVITY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD FOR PRODUCING A PROTEIN AND COMPOSITION | |
| DK3253382T3 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | |
| MX2018003183A (en) | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof. | |
| BR112016019176A2 (en) | il-21 antibodies | |
| MX2015012833A (en) | ANTIBIOTIC COMPOSITIONS OF CEFTOLOZANO. | |
| CY1119957T1 (en) | TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION | |
| EA201790773A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES | |
| BR112017024039B8 (en) | Vortioxetine pyroglutamate, pharmaceutical compositions and gel comprising the same, method for preparing a gel, and uses of vortioxetine pyroglutamate for manufacturing a medicament or gel | |
| BR112017024908A2 (en) | therapeutic uses of 4-chloroquinurenine | |
| MX391474B (en) | Cyclic peptides derived from CD44V6 for the treatment of cancer-related diseases and angiogenesis | |
| BR112016012002A2 (en) | VITANOLIDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| WO2016075305A3 (en) | Peptides derived from acinetobacter baumannii and their use in vaccination | |
| CR20180335A (en) | CD40L INHIBITING POLYPEPTIDES |